Inotiv Inc
NASDAQ:NOTV
Intrinsic Value
Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. [ Read More ]
The intrinsic value of one NOTV stock under the Base Case scenario is 39.16 USD. Compared to the current market price of 4.32 USD, Inotiv Inc is Undervalued by 89%.
Valuation Backtest
Inotiv Inc
Run backtest to discover the historical profit from buying and selling NOTV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Inotiv Inc
Current Assets | 190.7m |
Cash & Short-Term Investments | 22m |
Receivables | 92.2m |
Other Current Assets | 76.5m |
Non-Current Assets | 644.8m |
PP&E | 239.5m |
Intangibles | 394.6m |
Other Non-Current Assets | 10.6m |
Current Liabilities | 109.5m |
Accounts Payable | 30.7m |
Accrued Liabilities | 22.7m |
Other Current Liabilities | 56.1m |
Non-Current Liabilities | 471.9m |
Long-Term Debt | 370.9m |
Other Non-Current Liabilities | 100.9m |
Earnings Waterfall
Inotiv Inc
Revenue
|
585.2m
USD
|
Cost of Revenue
|
-408.1m
USD
|
Gross Profit
|
177.2m
USD
|
Operating Expenses
|
-170.9m
USD
|
Operating Income
|
6.3m
USD
|
Other Expenses
|
-39.5m
USD
|
Net Income
|
-33.3m
USD
|
Free Cash Flow Analysis
Inotiv Inc
What is Free Cash Flow?
NOTV Profitability Score
Profitability Due Diligence
Inotiv Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Inotiv Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
NOTV Solvency Score
Solvency Due Diligence
Inotiv Inc's solvency score is 24/100. The higher the solvency score, the more solvent the company is.
Score
Inotiv Inc's solvency score is 24/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NOTV Price Targets Summary
Inotiv Inc
According to Wall Street analysts, the average 1-year price target for NOTV is 15.81 USD with a low forecast of 10.1 USD and a high forecast of 26.25 USD.
Ownership
NOTV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NOTV Price
Inotiv Inc
Average Annual Return | 113.13% |
Standard Deviation of Annual Returns | 141.84% |
Max Drawdown | -97% |
Market Capitalization | 111.4m USD |
Shares Outstanding | 25 790 700 |
Percentage of Shares Shorted | 3.83% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The company is headquartered in West Lafayette, Indiana and currently employs 541 full-time employees. The firm focuses on providing drug developers with scientific research and analytical instrumentation. The firm operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.
Contact
IPO
Employees
Officers
The intrinsic value of one NOTV stock under the Base Case scenario is 39.16 USD.
Compared to the current market price of 4.32 USD, Inotiv Inc is Undervalued by 89%.